<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bortezomib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bortezomib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bortezomib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11168" href="/d/html/11168.html" rel="external">see "Bortezomib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F142137"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Velcade</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866103"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Bortezomib;</li>
<li>Bortezomib SDZ;</li>
<li>PMS-Bortezomib;</li>
<li>TARO-Bortezomib;</li>
<li>Velcade</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F142156"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Proteasome Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F142140"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Consecutive doses should be separated by at least 72 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information</b>: The reconstituted concentrations for IV and SUBQ administration are different; use caution when calculating the volume for each route and dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Consecutive doses should be separated by at least 72 hours. Consider antiviral prophylaxis for herpes virus infection during therapy. Consider initiating via the SUBQ route in patients at risk for or with preexisting neuropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7073a9e6-1a73-4b88-8882-0c814488709d">Antibody-mediated rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antibody-mediated rejection, treatment (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiac transplantation (off-label use): </i>
<b>IV:</b> 1.3 to 1.5 mg/m<sup>2</sup> typically given on days 1, 4, 8, and 11 (treatment frequency varies) for a total of 4 doses (treatment duration may vary) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25838326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25838326'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Kidney transplantation (off-label use): </i>
<b>Note:</b> Use in patients with early antibody-mediated rejection; benefit is not demonstrated in patients with late antibody-mediated rejection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29242250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29242250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, SUBQ: </b>1.3 mg/m<sup>2</sup> every 3 to 4 days for 4 doses; administer after plasmapheresis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21042239','lexi-content-ref-32075220','lexi-content-ref-25803498','lexi-content-ref-21852274','lexi-content-ref-20145517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21042239','lexi-content-ref-32075220','lexi-content-ref-25803498','lexi-content-ref-21852274','lexi-content-ref-20145517'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Liver transplantation (off-label use)<b>:</b></i>
<b> IV, SUBQ: </b>1.3 mg/m<sup>2</sup> once to twice weekly for up to 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34480762','lexi-content-ref-22681986']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34480762','lexi-content-ref-22681986'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lung transplantation (off-label use): </i>
<b>IV, SUBQ: </b>1.3 mg/m<sup>2</sup> once every 3 to 4 days for a total of 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20061929','lexi-content-ref-22202499','lexi-content-ref-33469943','lexi-content-ref-27988971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20061929','lexi-content-ref-22202499','lexi-content-ref-33469943','lexi-content-ref-27988971'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="30ef2c85-0c8d-4319-88a2-0a7e48d869b8">Cutaneous T-cell lymphoma, mycosis fungoides, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous T-cell lymphoma, mycosis fungoides, relapsed or refractory (off-label use):</b>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17709797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17709797'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2004e2c9-4cde-4cdf-87d1-19081e9c135a">Desensitization, kidney transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Desensitization, kidney transplantation (adjunctive) (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen (eg, following intravenous immunoglobulin and rituximab). Appropriate antiviral and antimicrobial prophylaxis should be employed during and following treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26844479']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26844479'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Kidney transplantation</i>
<i>(off-label use):</i>
<b> IV: </b>1.3 mg/m<sup>2</sup> every 3 days for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26844479']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26844479'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b28971b-5a9a-4dc4-bcdd-b523341b6807">Follicular lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Follicular lymphoma, relapsed or refractory (off-label use):</b>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with bendamustine and rituximab) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21239695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21239695'])">Ref</a></span>) <b>or</b> 1.6 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 35-day treatment cycle, in combination with bendamustine and rituximab for 5 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21810687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21810687'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93eb36d1-1a26-4aee-a8f5-0143f54b3306">Mantle cell lymphoma, previously untreated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mantle cell lymphoma, previously untreated (first-line therapy): Note:</b> Platelets should be ≥100,000/mm<sup>3</sup>, ANC should be ≥1,500/mm<sup>3</sup>, hemoglobin should be ≥8 g/dL, and nonhematologic toxicities should resolve to grade 1 or baseline prior to each cycle (cycle 2 and beyond).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VR-CAP (or VcR-CAP) regimen:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for 6 cycles (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone). If response first documented at cycle 6, treatment for an additional 2 cycles is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25738670','lexi-content-ref-30348538','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25738670','lexi-content-ref-30348538','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d720599-b903-4d54-ad61-549a6cebeac5">Mantle cell lymphoma, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mantle cell lymphoma, relapsed:</b>
<b>IV, SUBQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 17 cycles or for 4 cycles beyond initial complete response; discontinue for disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17001068','lexi-content-ref-19074748','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17001068','lexi-content-ref-19074748','lexi-content-ref-Manu.1'])">Ref</a></span>) <b>or</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with bendamustine and rituximab) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21239695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21239695'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51c9662c-fd25-4fff-a2b1-30a89c869424">Multiple myeloma, previously untreated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, previously untreated (first-line therapy): Note: </b>Bortezomib regimens also containing melphalan should be avoided in patients who are potential candidates for hematopoietic cell transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30932732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30932732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VMP regimen:</i>
<b>Note:</b> Platelets should be ≥70,000/mm<sup>3</sup>, ANC should be ≥1,000/mm<sup>3</sup>, and nonhematologic toxicities should resolve to grade 1 or baseline prior to initiation of any cycle of therapy. <b>IV, SUBQ: </b>1.3 mg/m<sup>2</sup> on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day treatment cycle for 4 cycles, followed by 1.3 mg/m<sup>2</sup> on days 1, 8, 22, and 29 of a 42-day treatment cycle for 5 cycles (in combination with melphalan and prednisone). Retreatment may be considered for patients who had previously responded to bortezomib (either as monotherapy or in combination) and who have relapsed at least 6 months after completing prior bortezomib therapy; initiate at the last tolerated dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23233713','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23233713','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>First-</i>
<i>line therapy, other dosing/combinations:</i>
<b> Note:</b> Refer to protocol for dosage adjustment details.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VRd (or RVd) regimen:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28017406','lexi-content-ref-32393732','lexi-content-ref-20385792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28017406','lexi-content-ref-32393732','lexi-content-ref-20385792'])">Ref</a></span>) <b>or</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for up to 8 induction cycles, followed by 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 42-day treatment cycle (as a single agent) for 4 maintenance cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22422823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22422823'])">Ref</a></span>) <b>or</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for 3 cycles, followed by conditioning/transplant, followed (after hematologic recovery in patients without progression) by 1.3 mg/m<sup>2</sup> (or last tolerated dose from cycle 3) on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25024076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25024076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VRd (or RVd) regimen:</i>
<b>SUBQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 35-day treatment cycle (in combination with lenalidomide and dexamethasone) for 9 induction cycles, followed by 1.3 mg/m<sup>2</sup> (or last tolerated dose from cycle 9) on days 1 and 15 of a 28-day treatment cycle (in combination with lenalidomide) for 6 consolidation cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29740809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29740809'])">Ref</a></span>) <b>or </b>1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with lenalidomide and dexamethasone) for 6 induction cycles (with mobilization after the third induction cycle), followed by conditioning/transplant, followed by 2 additional consolidation cycles 3 months after transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31484647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31484647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VTd regimen:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for 3 induction cycles (in combination with thalidomide and dexamethasone), followed by tandem transplant, followed by 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 every 35 days for 2 consolidation cycles (in combination with thalidomide and dexamethasone) beginning 3 months after second transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21146205','lexi-content-ref-22498745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21146205','lexi-content-ref-22498745'])">Ref</a></span>) <b>or </b>1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with thalidomide and dexamethasone) for 6 induction cycles followed by hematopoietic cell transplant and maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22791289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22791289'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VTd regimen:</i>
<b>SUBQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with thalidomide and dexamethasone) for 4 induction cycles, followed by conditioning/transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27002117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27002117'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CyBorD (or VCd) regimen:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with cyclophosphamide and dexamethasone), for up to 8 induction cycles followed by 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 42-day treatment cycle (as a single agent) for 4 maintenance cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22422823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22422823'])">Ref</a></span>) <b>or</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, 11 of a 28-day treatment cycle (in combination with cyclophosphamide and dexamethasone) for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22107129','lexi-content-ref-19225538']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22107129','lexi-content-ref-19225538'])">Ref</a></span>) <b>or </b>1.5 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 28-day treatment cycle for 4 cycles (may continue beyond 4 cycles) in combination with cyclophosphamide and dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22107129','lexi-content-ref-20413666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22107129','lexi-content-ref-20413666'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>PAD regimen:</i>
<b>IV:</b> Induction: 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with doxorubicin and dexamethasone) for 3 cycles, followed by conditioning/transplantation, and then maintenance bortezomib 1.3 mg/m<sup>2</sup> once every 2 weeks for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22802322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22802322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Daratumumab-containing regimens:</i>
<b>SUBQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day cycle (in combination with daratumumab, lenalidomide, and dexamethasone; DVRd regimen) for 4 induction cycles and 2 post-transplant consolidation cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32325490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32325490'])">Ref</a></span>)<b> or</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day cycle (in combination with daratumumab, thalidomide, and dexamethasone; DVTd regimen) for up to 4 pretransplant induction cycles and 2 posttransplant consolidation cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31171419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31171419'])">Ref</a></span>) <b>or </b>1.3 mg/m<sup>2</sup> two times a week during weeks 1, 2, 4, and 5 of the first 6-week cycle (cycle 1; 8 doses/cycle), followed by 1.3 mg/m<sup>2</sup> once a week during weeks 1, 2, 4, and 5 for eight 6-week cycles (cycles 2 to 9; 4 doses/cycle) in combination with daratumumab, melphalan, and prednisone; after cycle 9, daratumumab is continued as a single agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29231133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29231133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VD regimen:</i>
<b>IV:</b> Induction: 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with dexamethasone) for 4 cycles, followed by autologous cell transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20823406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20823406'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VTD-PACE regimen</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Induction</i>: <b>SUBQ:</b> 1 mg/m<sup>2</sup> on days 1, 4, 8, and 11 (in combination with thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) for 2 cycles administered ≤8 weeks apart, followed by autologous hematopoietic cell transplant (HCT) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17593024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17593024'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Consolidation</i>: <b>SUBQ:</b> 1 mg/m<sup>2</sup> on days 1, 4, 8, and 11 (in combination with thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) for 2 cycles. Consolidation cycle 1 is to begin 6 weeks to 4 months following last autologous HCT and cycle 2 is to begin 2 to 4 months following cycle 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17593024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17593024'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance</i>: <b>SUBQ:</b> 1 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day cycle (in combination with thalidomide and dexamethasone) for 1 year. Maintenance is to begin 1 to 4 months following cycle 2 of consolidation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17593024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17593024'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients ≥65 years of age:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 35-day treatment cycle for 9 cycles, in combination with <b>either</b> melphalan and prednisone or melphalan, prednisone, and thalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20807892','lexi-content-ref-20940200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20807892','lexi-content-ref-20940200'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance therapy in transplant-eligible patients (following induction and transplant; in patients intolerant to or unable to receive maintenance therapy with lenalidomide):</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> once every 2 weeks for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30932732','lexi-content-ref-22802322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30932732','lexi-content-ref-22802322'])">Ref</a></span>). For high-risk patients, maintenance therapy with a proteosome inhibitor ± lenalidomide may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30932732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30932732'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac522d92-c8b2-419c-959b-57ffc7ab0312">Multiple myeloma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed or refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy:</i>
<b>IV, SUBQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle. Therapy extending beyond 8 cycles may be administered by the standard schedule or may be given once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest (days 23 through 35). Retreatment may be considered for patients who had previously responded to bortezomib (either as monotherapy or in combination) and who have relapsed at least 6 months after completing prior bortezomib therapy; initiate at the last tolerated dose. Administer twice weekly for 2 weeks on days 1, 4, 8, and 11 of a 21-day treatment cycle (either as a single agent or in combination with dexamethasone) for a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relapsed or refractory disease, other dosing/combinations: </i>
<b>Note:</b> Refer to protocol for dosage adjustment details.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VRd (or RVd) regimen:</i>
<b>IV:</b> 1 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for up to 8 cycles, followed by maintenance therapy (if response or stable disease) of 1 mg/m<sup>2</sup> (or the dose tolerated in cycle 8) on days 1 and 8 of a 21-day treatment cycle (± lenalidomide and/or dexamethasone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24429336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24429336'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>DVd regimen:</i>
<b>SUBQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 every 21 days (in combination with daratumumab and dexamethasone) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27557302','lexi-content-ref-36413710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27557302','lexi-content-ref-36413710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VPd regimen:</i>
<b>IV, SUBQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with pomalidomide and dexamethasone) for 8 cycles, followed by 1.3 mg/m<sup>2</sup> on days 1 and 8 of a 21-day treatment cycle (in combination with pomalidomide and dexamethasone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31097405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31097405'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>SVd regimen:</i>
<b>SUBQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 every 35 days (in combination with selinexor and dexamethasone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33189178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33189178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bortezomib/Doxorubicin (liposomal) regimen:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with liposomal doxorubicin) for at least 8 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17679727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17679727'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CyBorD (or VCD) regimen:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 8 cycles, followed by 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 35-day treatment cycle for up to 3 cycles (in combination with cyclophosphamide and dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17614819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17614819'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bendamustine/Bortezomib/Dexamethasone regimen:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with bendamustine and dexamethasone) for 4 cycles (if no response) or for up to a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24227817']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24227817'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b4dfc2ab-7ab4-45d1-afc0-e6bf75638548">Peripheral T-cell lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral T-cell lymphoma, relapsed or refractory (off-label use): IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17709797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17709797'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4d4718b-e0ee-4bda-871f-113cd0b52efe">Systemic light chain amyloidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic light chain amyloidosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (with or without dexamethasone) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20085941','lexi-content-ref-21562045','lexi-content-ref-25202139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20085941','lexi-content-ref-21562045','lexi-content-ref-25202139'])">Ref</a></span>) <b>or</b> 1.6 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 35-day cycle for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21562045','lexi-content-ref-25202139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21562045','lexi-content-ref-25202139'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i>
<b> Note:</b> Refer to protocols for dosage adjustment details.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CyBorD (or VCD or CVD) regimen: </i>
<b>IV</b>: 1 mg/m<sup>2</sup> on days 1, 4, 8, and 11 (in combination with cyclophosphamide and dexamethasone) for a maximum of 8 cycles; bortezomib dose could be increased to 1.3 mg/m<sup>2</sup> if well-tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22331187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22331187'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Daratumumab-CyBorD (or VCD) regimen: </i>
<b>SUBQ</b>: 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 28-day cycle (in combination with daratumumab hyaluronidase, cyclophosphamide, and dexamethasone) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34192431']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34192431'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bortezomib/melphalan/dexamethasone regimen:</i>
<b>IV or SUBQ</b>: 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 28-day cycle (in combination with melphalan and dexamethasone) for 2 cycles, followed by 1.3 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 35-day cycle (in combination with melphalan and dexamethasone) for 6 additional cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32730181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32730181'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebda9a81-6b8d-4064-acf9-5c892f36549f">Waldenström macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia (off-label use): Note: </b>The Tenth International Workshop on Waldenström Macroglobulinemia prefers administering bortezomib SUBQ (if possible) (IWWM [Castillo 2020]). Refer to protocols for dosage adjustment details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial therapy:</i>
<b>IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with dexamethasone and rituximab) for 4 cycles, followed by a 12-week rest, then an additional 4 cycles for a total of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19506160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19506160'])">Ref</a></span>) <b>or </b>1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for 1 cycle, followed by 1.6 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 35-day treatment cycle for 4 cycles; cycles 2 and 5 also included dexamethasone and rituximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24004667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24004667'])">Ref</a></span>) <b>or </b>1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (as a single agent); continue until disease progression or until 2 cycles after achieving a complete response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17353550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17353550'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relapsed or refractory disease:</i>
<b>IV:</b> 1.6 mg/m<sup>2</sup> on days 1, 8, and 15 of a 28-day treatment cycle for 6 cycles (in combination with rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20142586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20142586'])">Ref</a></span>) <b>or </b>1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle (as a single agent); continue until disease progression or until 2 cycles after achieving a complete response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17353550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17353550'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991209"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: <b>IV, SUBQ:</b></b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25803498','lexi-content-ref-26976420','lexi-content-ref-21479634','lexi-content-ref-21778706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25803498','lexi-content-ref-26976420','lexi-content-ref-21479634','lexi-content-ref-21778706'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, SUBQ:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzability unknown but likely minimal given large V<sub>d</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, SUBQ:</b> No dosage adjustment is necessary; when scheduled dose falls on a dialysis day, administer after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26976420','lexi-content-ref-21479634','lexi-content-ref-21778706','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26976420','lexi-content-ref-21479634','lexi-content-ref-21778706','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzability unknown but likely minimal given large V<sub>d</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): <b>IV, SUBQ:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: IV, SUBQ:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): <b>IV, SUBQ:</b></b>No dosage adjustment necessary; when scheduled dose falls on a PIRRT day, administer after PIRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988412"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (bilirubin ≤ ULN and AST &gt;ULN or bilirubin &gt;1 to 1.5 times ULN and any AST): No initial dose adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22394984','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22394984','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) and severe impairment (bilirubin &gt;3 times ULN and any AST): Reduce initial dose to 0.7 mg/m<sup>2</sup> in the first cycle; based on patient tolerance, may consider dose escalation to 1 mg/m<sup>2</sup> or further dose reduction to 0.5 mg/m<sup>2</sup> in subsequent cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22394984','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22394984','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute hepatotoxicity during treatment:</b> Interrupt bortezomib treatment (to assess reversibility) if acute liver failure, hepatitis, increased transaminases, and/or hyperbilirubinemia occur; information on bortezomib rechallenge is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block doo drugH1Div" id="F20339769"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology </i>
<i>guidelines</i>
<i> for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F142157"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>Note:</b> Hematologic toxicity may also require platelet transfusion, supportive care, and/or myeloid growth factors as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (previously untreated, in combination with melphalan and prednisone): Note:</b> Refer to protocol for specific dosage modifications for melphalan and prednisone.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Bortezomib Recommended Dosage Modifications for Adverse Reactions in Previously Untreated Multiple Myeloma</b></caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Bortezomib dosage modification</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Hematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Neutropenia</p></td>
<td align="center">
<p style="text-indent:0em;">ANC &lt;750/mm<sup>3</sup> on bortezomib dosing day (except day 1)</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold bortezomib.</p>
<p style="text-indent:0em;">If several bortezomib doses in consecutive cycles are withheld due to toxicity, reduce bortezomib dose by one dose level (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;">Platelets ≤30,000/mm<sup>3</sup> on bortezomib dosing day (except day 1)</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold bortezomib.</p>
<p style="text-indent:0em;">If several bortezomib doses in consecutive cycles are withheld due to toxicity, reduce bortezomib dose by one dose level (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Nonhematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Other nonhematologic adverse reactions (excluding neuropathy)</p></td>
<td align="center">
<p style="text-indent:0em;">≥ Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold bortezomib until toxicity resolves to grade 1 or baseline; may reinitiate with one dose level reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mantle cell lymphoma (previously untreated, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone): Note:</b> Refer to protocol for specific dosage modifications for rituximab, cyclophosphamide, doxorubicin, and prednisone.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Bortezomib Recommended Dosage Modifications for Adverse Reactions in Previously Untreated Mantle Cell Lymphoma</b></caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Bortezomib dosage modification</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Hematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Neutropenia</p></td>
<td align="center">
<p style="text-indent:0em;">≥ Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold bortezomib for up to 2 weeks until ANC ≥750/mm<sup>3</sup>.</p>
<p style="text-indent:0em;">
<i>ANC ≥750/mm<sup>3</sup> within 2 weeks of interruption</i>: Resume bortezomib with one dose level reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).</p>
<p style="text-indent:0em;">
<i>Resolution of ANC ≥750/mm<sup>3</sup> does not occur within 2 weeks of interruption</i>: Discontinue bortezomib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;">Platelets &lt;25,000/mm<sup>3</sup> on bortezomib dosing day</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold bortezomib for up to 2 weeks until platelets ≥25,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;">
<i>Platelets ≥25,000/mm<sup>3</sup> within 2 weeks of interruption</i>: Resume bortezomib with one dose level reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).</p>
<p style="text-indent:0em;">
<i>Resolution of platelets ≥25,000/mm<sup>3</sup> does not occur within 2 weeks of interruption</i>: Discontinue bortezomib.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Nonhematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Other nonhematologic adverse reactions (excluding neuropathy)</p></td>
<td align="center">
<p style="text-indent:0em;">≥ Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold bortezomib until toxicity resolves to ≤grade 2; may reinitiate with one dose level reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Relapsed multiple myeloma and relapsed mantle cell lymphoma: Note:</b> Refer to protocol for specific dosage modifications for other concomitant anticancer therapies.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Bortezomib Recommended Dosage Modifications for Adverse Reactions in Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma</b></caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Hematologic toxicity</b></p></td>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold until toxicity resolved; may reinitiate with a 25% dose reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Nonhematologic toxicity (excluding neuropathy)</b></p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold until toxicity resolved; may reinitiate with a 25% dose reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Other</b>
<b> nonhematologic toxicities including neuropathic pain and/or peripheral sensory, motor, or autonomic neuropathy (all indications):</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Bortezomib</b>
<b> Recommended Dosage Modifications for Adverse Reactions (All Indications)</b></caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Bortezomib dosage modification</b></p></th></tr>
<tr>
<th align="left" colspan="3">
<p style="text-indent:0em;">
<b>Nonhematologic toxicity</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> PRES = Posterior reversible leukoencephalopathy syndrome; TTP/HUS = Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Cardiopulmonary toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Any</p></td>
<td align="center">
<p style="text-indent:0em;">Promptly evaluate with new or worsening symptoms; therapy interruption may be required.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">GI toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Any</p></td>
<td align="center">
<p style="text-indent:0em;">GI symptoms may require antiemetics or antidiarrheals. Administer fluid and electrolytes to prevent dehydration; interrupt therapy for severe symptoms.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hyper- or hypoglycemia (in patients with diabetes)</p></td>
<td align="center">
<p style="text-indent:0em;">Any</p></td>
<td align="center">
<p style="text-indent:0em;">May require adjustment of diabetes medications.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hypotension (orthostatic or postural)</p></td>
<td align="center">
<p style="text-indent:0em;">Any</p></td>
<td align="center">
<p style="text-indent:0em;">May require adjustment of antihypertensive medication, hydration, and mineralocorticoids and/or sympathomimetics.</p></td></tr>
<tr>
<td align="left" rowspan="5">
<p style="text-indent:0em;">Neuropathic pain and/or peripheral sensory, motor, or autonomic neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;">Any</p></td>
<td align="center">
<p style="text-indent:0em;">Consider SUBQ administration in patients with preexisting or at high risk for peripheral neuropathy.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1 (asymptomatic; deep tendon reflex loss or paresthesia without pain or loss of function)</p></td>
<td align="center">
<p style="text-indent:0em;">No dose modification required.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1 with pain <b>or</b></p>
<p style="text-indent:0em;">Grade 2 (moderate symptoms; limiting instrumental activities of daily living)</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce bortezomib dose to 1 mg/m<sup>2</sup>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2 with pain <b>or </b></p>
<p style="text-indent:0em;">Grade 3 (severe symptoms; limiting self-care activities of daily living)</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold bortezomib until toxicity resolves; upon resolution, resume bortezomib at a reduced dose of 0.7 mg/m<sup>2</sup>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4 (life-threatening consequences with urgent intervention indicated and/or severe autonomic neuropathy)</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue bortezomib.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">PRES<sup class="footnote-number">a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Suspected</p></td>
<td align="center">
<p style="text-indent:0em;">Evaluate promptly any new onset or worsening neurologic symptoms.</p>
<p style="text-indent:0em;">Perform MRI to confirm diagnosis.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Confirmed</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue bortezomib. The safety of reinitiating bortezomib in patients previously experiencing PRES is unknown.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Thrombotic microangiopathy (including TTP/HUS<sup class="footnote-number">a</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Suspected</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold bortezomib and evaluate promptly; may resume bortezomib if diagnosis of TTP/HUS is excluded.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Confirmed</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue bortezomib. The safety of reinitiating bortezomib in patients previously experiencing TTP/HUS is unknown.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F2655956"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F142110"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11%), anorexia (14% to 21%), constipation (24% to 34%), decreased appetite (11%), diarrhea (19% to 52%; grade 3: 1% to 7%; grades ≥3: 7%), nausea (14% to 52%; grade 3: 2%; grades ≥3: 3%), vomiting (9% to 29%; grade 3: 2%; grades ≥3: 3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (12% to 23%; grades ≥3: ≤6%), leukopenia (18% to 20%; grade 3: 5%; grade 4: 1%), neutropenia (5% to 27%; grades ≥3%: 2% to 18%), thrombocytopenia (16% to 52%; grades ≥3%: 3% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (herpes zoster infection and reactivation: 6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (10% to 18%), fatigue (7% to 52%), headache (10% to 19%), malaise (≤59%), neuralgia (23%), paresthesia (7% to 19%), peripheral neuropathy (including peripheral motor neuropathy and peripheral sensory neuropathy: 28% to 54%; grades ≥2: 24% to 39%; grades ≥3: 6% to 15%; grade 4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (7% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (8% to 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac disorder (treatment emergent: 8%), cardiogenic shock (≤1%), heart failure (≤1%), hypotension (including orthostatic hypotension: 8% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (grades ≥3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (mostly redness: 6%), irritation at injection site (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute pulmonary edema (≤1%), pulmonary edema (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Cardiovascular: Syncope</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (reported reactions may have occurred with either monotherapy or combination therapy):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, aggravated atrial fibrillation, angina pectoris, atrial flutter, atrioventricular block, bradycardia, cerebrovascular accident, decreased left ventricular ejection fraction, deep vein thrombosis, edema, facial edema, hemorrhagic stroke, hypersensitivity angiitis, hypertension, ischemic heart disease, limb embolism, pericardial effusion, pericarditis, peripheral edema, portal vein thrombosis, prolonged QT interval on ECG, pulmonary embolism, septic shock, sinoatrial arrest, subdural hematoma, torsades de pointes, transient ischemic attacks, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amyloid heart disease, dehydration, hyperkalemia, hypernatremia, hyperuricemia, hypocalcemia, hypokalemia, hyponatremia, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, cholestasis, duodenitis (hemorrhagic), dysgeusia, dyspepsia, dysphagia, fecal impaction, gastritis (hemorrhagic), gastroenteritis, gastroesophageal reflux disease, hematemesis, intestinal obstruction, intestinal perforation, melena, oral candidiasis, paralytic ileus, peritonitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation, febrile neutropenia, lymphocytopenia, oral mucosal petechiae</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites, hepatic failure, hepatic hemorrhage, hepatitis, hyperbilirubinemia, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, drug-induced hypersensitivity reaction, hypersensitivity reaction, type III hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Aspergillosis, bacteremia, listeriosis, toxoplasmosis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Catheter complication, catheter infection, erythema at injection site, pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, ataxia, cerebral hemorrhage, chills, coma, confusion, cranial nerve palsy, dysarthria, dysautonomia, dysesthesia, encephalopathy, insomnia, mental status changes, motor dysfunction, paralysis, postherpetic neuralgia, psychosis, seizure (tonic-clonic), spinal cord compression, suicidal ideation, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, bone fracture, limb pain, myalgia, ostealgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, conjunctival infection, diplopia, eye irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Bilateral hydronephrosis, nephrolithiasis, proliferative glomerulonephritis, renal failure syndrome (including acute kidney injury and chronic renal failure)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome, aspiration pneumonia, atelectasis, bronchitis, cough, dyspnea on exertion, epistaxis, exacerbation of chronic obstructive pulmonary disease, hemoptysis, hypoxia, interstitial pneumonitis, laryngeal edema, nasopharyngitis, pleural effusion, pneumonia, pneumonitis, pulmonary hypertension, pulmonary infiltrates (including diffuse), respiratory distress, respiratory tract infection, sinusitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac tamponade</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome, Sweet’s syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ischemic colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic-uremic syndrome, thrombotic microangiopathy, thrombotic thrombocytopenic purpura, tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Guillain-Barre syndrome, herpes meningoencephalitis, peripheral demyelinating polyneuropathy, progressive multifocal leukoencephalopathy, reversible posterior leukoencephalopathy syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis, blindness, chalazion (Fraunfelder 2016), ocular herpes simplex, optic neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (bilateral)</p></div>
<div class="block coi drugH1Div" id="F142123"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (excluding local reactions) to bortezomib, boron, boric acid (generic product), glycine (some generic products), mannitol (Velcade, some generic products), or any component of the formulations; administration via the intrathecal route.</p></div>
<div class="block war drugH1Div" id="F142108"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Hematologic toxicity, including grade 3 and 4 neutropenia and thrombocytopenia may occur; risk is increased in patients with pretreatment platelet counts &lt;75,000/mm<sup>3</sup>. Nadirs generally occur following the last dose of a cycle and recover prior to the next cycle. Hemorrhage (GI and intracerebral) due to low platelet count has been observed. Neutropenic fever has been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Acute development or exacerbation of HF and new onset decreased left ventricular ejection fraction (LVEF) have been reported with bortezomib; some cases have occurred in patients without risk factors for HF and/or decreased LVEF. Isolated case of QTc prolongation have been reported with bortezomib.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Nausea, vomiting, diarrhea, constipation, or ileus may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Acute liver failure has been reported (rarely) in patients receiving multiple concomitant medications and with serious underlying conditions. Hepatitis, transaminase increases, and hyperbilirubinemia have also been reported. Limited data exist for patients that have been rechallenged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Herpes reactivation: Herpes (zoster and simplex) reactivation has been reported with bortezomib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, angioedema, and laryngeal edema have been reported with bortezomib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Bortezomib may cause hypotension (including postural and orthostatic). Patients with a history of syncope, receiving medications associated with hypotension, and those who are dehydrated may be at increased risk of hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral neuropathy: Bortezomib may cause or worsen peripheral neuropathy (usually sensory but may be mixed sensorimotor); risk may be increased with previous use of neurotoxic agents or preexisting peripheral neuropathy (in patients with preexisting neuropathy, use only after risk versus benefit assessment). The incidence of grades 2 and 3 peripheral neuropathy may be lower with SUBQ route (compared to IV). The majority of patients with ≥ grade 2 peripheral neuropathy have improvement in or resolution of symptoms with dose adjustments or discontinuation. In a study of patients ≥65 years of age receiving a weekly bortezomib schedule with combination chemotherapy, the incidence of peripheral neuropathy was significantly reduced without an effect on outcome (Palumbo 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Posterior reversible leukoencephalopathy syndrome: Posterior reversible leukoencephalopathy syndrome (PRES, formerly RPLS) has been reported (rarely). Symptoms of PRES include confusion, headache, hypertension, lethargy, seizure, blindness and/or other vision, or neurologic disturbances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy has been rarely observed; symptoms may include confusion, loss of balance, vision disturbances, reduced strength or weakness in an arm/leg.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Pulmonary disorders (some fatal) including pneumonitis, interstitial pneumonia, lung infiltrates, and acute respiratory distress syndrome (ARDS) have been reported. Pulmonary hypertension (without left heart failure or significant pulmonary disease) has been reported rarely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic microangiopathy: Cases (some fatal) of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome has been reported with bortezomib; risk is increased in patients with high tumor burden prior to treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Hyper- and hypoglycemia may occur in patients with diabetes receiving oral hypoglycemics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: <b>For SUBQ or IV administration only.</b> Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Bortezomib should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep bortezomib in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Bortezomib should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration. The reconstituted concentrations for IV and SUBQ administration are different; use caution when calculating the volume for each route and dose. The manufacturers provide stickers to facilitate identification of the route for reconstituted vials. Some bortezomib products may not be approved for SUBQ administration; refer to specific product labeling for approved administration routes.</p></div>
<div class="block foc drugH1Div" id="F142118"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3.5 mg/1.4 mL (1.4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Velcade: 3.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg (1 ea); 2.5 mg (1 ea); 3.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3.5 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F142106"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323023"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Bortezomib Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.5MG/1.4ML (per mL): $102.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Bortezomib Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $97.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $230.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.5 mg (per each): $42.00 - $1,827.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Bortezomib Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.5 mg (per each): $1,923.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Velcade Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.5 mg (per each): $1,923.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866104"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Velcade: 3.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg (1 ea); 3.5 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F142120"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Reconstituted solution concentrations for IV and SUBQ administration are different; use caution when calculating the volume for each route and dose. Consider SUBQ administration in patients with preexisting or at high risk for peripheral neuropathy. Some bortezomib products may not be approved for SUBQ administration; refer to specific product labeling for approved administration routes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer via rapid IV push (3 to 5 seconds). When administering in combination with rituximab for first-line therapy of mantle cell lymphoma, administer bortezomib prior to rituximab.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> SUBQ administration of bortezomib 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle has been studied in patients with relapsed multiple myeloma; doses were administered SUBQ (concentration of 2.5 mg/mL) into the thigh or abdomen, rotating the injection site with each dose; injections at the same site within a single cycle were avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21507715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21507715'])">Ref</a></span>). Response rates were similar to IV administration; decreased incidence of grade 3 or higher adverse events were observed with SUBQ administration. Administer at least 1 inch from an old site and never administer to tender, bruised, erythematous, or indurated sites. If injection site reaction occurs, the more dilute 1 mg/mL concentration may be used SUBQ (or IV administration of 1 mg/mL concentration may be considered).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>For SUBQ or IV administration only; fatalities have been reported with inadvertent intrathecal administration.</b> Bortezomib should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>
<div class="block hazard drugH1Div" id="F49130903"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F142119"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mantle cell lymphoma:</b> Treatment of mantle cell lymphoma in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma:</b> Treatment of multiple myeloma in adults.</p></div>
<div class="block off-label drugH1Div" id="F25475219"><span class="drugH1">Use: Off-Label: Adult</span><p>Antibody-mediated rejection in cardiac transplantation (treatment); Antibody-mediated rejection, kidney transplantation (treatment); Antibody-mediated rejection, liver transplantation (treatment, refractory); Antibody-mediated rejection, lung transplantation (treatment); Cutaneous T-cell lymphoma, mycosis fungoides, relapsed or refractory; Desensitization, kidney transplantation; Follicular lymphoma, relapsed or refractory; Peripheral T-cell lymphoma, relapsed or refractory; Systemic light-chain amyloidosis; Waldenström macroglobulinemia</p></div>
<div class="block mst drugH1Div" id="F3401586"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bortezomib may be confused with bosutinib, carfilzomib, ixazomib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The reconstituted concentrations for IV and SUBQ administration are different; use caution when calculating the volume for each route and dose. The manufacturers provide stickers to facilitate identification of the route for reconstituted vials.</p>
<p style="text-indent:-2em;margin-left:4em;">For SUBQ or IV administration only. Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Bortezomib should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep bortezomib in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Bortezomib should <b>NOT</b> be delivered to the patient at the same time with any medications intended for intrathecal administration.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F142150"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F142112"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Bortezomib may enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Bortezomib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Bortezomib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Bortezomib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bortezomib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Green Tea: May diminish the antineoplastic effect of Bortezomib. Management: Advise patients to avoid concurrent use of green tea extract and other green tea products, particularly at higher doses or amounts, during treatment with bortezomib when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May diminish the therapeutic effect of Bortezomib. Specifically, the vitamin C (ascorbic acid) found in many multivitamins may impair the clinical effects of bortezomib. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy.  It is likely unnecessary, though, to advise patients to avoid dietary sources of vitamin C.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Bortezomib. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins with bortezomib.  It is probably unnecessary to restrict or limit vitamin C-containing foods/beverages.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May diminish the therapeutic effect of Bortezomib. Specifically, vitamin C may decrease bortezomib therapeutic effects. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy.  It is likely unnecessary, though, to advise patients to avoid dietary sources of vitamin C.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095591"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to initiating therapy in patients who could become pregnant. Patients who could become pregnant should avoid becoming pregnant during bortezomib treatment and use effective contraception during therapy and for 7 months following bortezomib treatment. Patients with partners who could become pregnant should use effective contraception during and for 4 months following bortezomib treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Bortezomib may potentially affect male or female fertility (based on the mechanism of action).</p></div>
<div class="block pri drugH1Div" id="F142126"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and on findings in animal reproduction studies, in utero exposure to bortezomib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F142127"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if bortezomib is present in breast milk. The manufacturer recommends lactating patients avoid breastfeeding during and for 2 months following bortezomib treatment.</p></div>
<div class="block dic drugH1Div" id="F6894443"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Green tea and green tea extracts may diminish the therapeutic effect of bortezomib and should be avoided (Golden 2009). Avoid grapefruit juice. Avoid additional, nondietary sources of ascorbic acid supplements, including multivitamins containing ascorbic acid (may diminish bortezomib activity) during treatment, especially 12 hours before and after bortezomib treatment (Perrone 2009).</p></div>
<div class="block mop drugH1Div" id="F142116"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelets (monitor frequently throughout therapy); liver function tests (in patients with existing hepatic impairment); kidney function. Monitor blood glucose (in patients with diabetes). Verify pregnancy status prior to therapy initiation in patients who could become pregnant. Monitor BP. Monitor for signs/symptoms of peripheral neuropathy (consider SUBQ administration in patients with preexisting or at high risk for peripheral neuropathy), dehydration, hypotension (use with caution in patients with dehydration, history of syncope, or taking medications associated with hypotension), posterior reversible leukoencephalopathy syndrome, progressive multifocal leukoencephalopathy, tumor lysis syndrome, or hyper-/hypoglycemia. Monitor baseline chest x-ray and then periodic pulmonary function testing (with new or worsening pulmonary symptoms). Monitor closely in patients with risk factors for heart failure or existing heart disease.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017], (ESC [Lyon 2022]). Assess BP at baseline and each clinical visit (also consider weekly home monitoring for initial 3 months, then monthly thereafter); assess natriuretic peptide at baseline for high and very high-risk patients and consider at each cycle for the first 6 cycles; consider checking natriuretic peptide at baseline for low- and moderate-risk patients; obtain a baseline echocardiography in all patients (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F142107"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bortezomib inhibits proteasomes, enzyme complexes which regulate protein homeostasis within the cell. Specifically, it reversibly inhibits chymotrypsin-like activity at the 26S proteasome, leading to activation of signaling cascades, cell-cycle arrest, and apoptosis.</p></div>
<div class="block phk drugH1Div" id="F142122"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: ~498 to 1,884 L/m<sup>2</sup>; distributes widely to peripheral tissues.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~83%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic primarily via CYP2C19, CYP3A4, and CYP1A2 and to a lesser extent CYP2D6 and CYP2C9; forms metabolites (inactive) via deboronization followed by hydroxylation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Single dose: IV: 9 to 15 hours; Multiple dosing: 1 mg/m<sup>2</sup>: 40 to 193 hours; 1.3 mg/m<sup>2</sup>: 76 to 108 hours.</p></div>
<div class="block phksp drugH1Div" id="F51154016"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Dose-normalized mean AUC levels were increased by ~60% in patients with moderate or severe hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F142128"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib spc | Bortezon | Veelbore</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Biliodim | Borater | Bortezomib everex | Bortezomib Sandoz | Bortmex | Bozob | Bromadene | Egidon | Eugene | Gysaty | Miasoma | Multizom | Ninib | Simbiote | Zefra</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib hcs | Bortezomib Hikma | Bortezomib mylan | Velcade</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bortezom | Bortezomib accord | Bortezomib juno | Bortezomib Sandoz | Dbl bortezomib | Velcade</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib ab | Bortezomib accord | Bortezomib fresenius kabi | Bortezomib mylan | Bortezomib reddy | Bortezomib Sandoz | Bortezomib teva | Velcade</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bortega | Bortezocon | Bortezomib actavis | Bortezomib Sandoz | Vortemyel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bormib | Bortezomibe | Bortyz | Bozored | Mibo | Mielocade | Tovar | Velcade | Verazo | Zomi | Zomyle</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib Sandoz | Bortezomib zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Egybort</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bicavan | Bozix | Bozob</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Velcade</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Belocef | Borteleg | Bortemix | Borten | Bortesun | Bortezomib Sandoz | Bortezomseven | Botemib | Bozib | Egidon | Fizomeb | Mibzo | Nubortez | Porix | Rebtyk | Tebide | Tenimib | Tizob | Unitezo | Velcade | Vortyz | Zomitec</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bortega | Bortezomib accord | Bortezomib actavis | Bortezomib adamed | Bortezomib ebewe | Bortezomib fresenius kabi | Bortezomib glenmark | Bortezomib zentiva | Zegomib</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bortezom accord bb farma | Bortezomib accord | Bortezomib beta | Bortezomib cipla | Bortezomib denk | Bortezomib hexal | Bortezomib Hikma | Bortezomib hospira | Bortezomib medac | Bortezomib mylan | Bortezomib puren | Bortezomib ratiopharm | Bortezomib ribosepharm | Bortezomib sun | Bortezomib zentiva | Velcade</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Velcade | Votobel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Botemib | Bozob | Miasoma</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib actavis | Bortezomib hospira | Bortezomib sun | Bortezomib teva | Velcade</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Velcade</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib aurovitas | Bortezomib cipla | Bortezomib dr. reddys | Bortezomib farmoz | Bortezomib fresenius kabi | Bortezomib kern | Bortezomib krka | Bortezomib mylan | Bortezomib sun | Bortezomib teva | Bortezomib tillomed | Velcade</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Bortenat | Bortezomib msn</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib reddy | Bortezomib sun | Velcade</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib ohre pharma | Bortezomib reddy pharma | Bortezomib viatris | Bortezomib zentiva | Velcade</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib mylan | Bortezomib reddys | Bortezomib Sandoz | Velcade</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Velcade</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib pliva | Velcade</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib actavis | Bortezomib msn | Bortezomib Sandoz | Bortezomib teva | Velcade | Vortemyel | Zegomib</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bormib | Bortecade | Borteloma | Bortero | Velcade</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib krka | Bortezomib rowex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Biocure | Bortecad | Bortemib | Bortenat | Bortero | Bortesam | Bortetor | Bortetrust | Bortezom | Bortiad | Bortirel | Bortrac | Borviz | Egybort | Mibor | Myezom | Mylosome | MyZomib | Ortez | Proteoz | Rolcade | Velcade | Zomib | Zortemib</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib fresenius kabi | Bortezomib Hikma | Bortezomib medac | Bortezomib mylan | Bortezomib reddys | Bortezomib sun | Bortezomib teva | Bortezomib zentiva | Velcade</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Brotex | Veelbore</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib dsep | Bortezomib sawai | Bortezomib towa | Velcade</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bortemib | Bortesun | Bortimore | Velcade</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Belzomib | Bortevel | Protezomib | Tezobel | Tezobell | Tezomin | Velcade | Velkin | Velzomib</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Velcade</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Borcade | Velcade</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib fresenius kabi | Bortezomib sun | Sangrel | Vortemyel</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib fresenius kabi | Bortezomib sun | Velcade | Vortemyel</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Velcade</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bemoncaz | Bizmi | Bomib | Elomaziv | Exfucikanet | Misecade | Rebtyk | Velcade | Zuricade</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Accord bortezomib | Bortero | Myborte | Retrox | Velcade</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib adamed | Bortezomib B-medical | Bortezomib fresenius kabi | Bortezomib krka | Bortezomib reddy | Bortezomib Sandoz | Bortezomib sun | Bortezomib zentiva | Velcade</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib mylan | Velcade</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib dr. reddys | Bortezomib juno | Velcade</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Botemib | Bozob | Mibor | Topneuter | Velcade | Velcord</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bezom | Biomib | Bortesum | Bortether | Mylocure | Pfizer bortezomib | Velcade | Zyocade</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib pharmidea | Egybort</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib actavis | Bortezomib adamed | Bortezomib aurovitas | Bortezomib fresenius kabi | Bortezomib medac | Bortezomib sun | Velcade | Vortemyel</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Velcade</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib fresenius kabi | Bortezomib generis | Bortezomib krka | Bortezomib tecnigen | Bortezomib teva | Velcade</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Borater | Bortezomib bauel top | Bortezomib bioteng | Bortezomib catedral | Bortezomib cellofarm | Bortezomib gemepe | Bortezomib imedic | Bortezomib indufar | Bortezomib libra | Bortezomib prosalud | Bortezomib Sandoz | Botemib | Bozob</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Velcade | Velzome</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bortega | Bortezomib accord | Bortezomib actavis | Bortezomib glenmark | Bortezomib hospira | Bortezomib reddys | Bortezomib Sandoz | Bortezomib sun | Bortezomib zentiva | Vortemyel</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bartizar | Boramilan | Boramilan fs | Bortezol | Bortezomib canon | Milanfore | Milatib | Myborte | Velcade | Velmib | Verozomib</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib spc | Valtroza | Veelbore</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib avansor | Bortezomib fresenius kabi | Bortezomib krka | Bortezomib medac | Bortezomib mylan | Bortezomib reddy | Bortezomib sun | Bortezomib teva | Velcade</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Velcade</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib accord | Bortezomib actavis | Bortezomib mylan | Bortezomib Sandoz | Bortezomib teva | Gloftrinid | Velcade</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bortega | Bortezomib accord | Bortezomib actavis | Bortezomib glenmark | Bortezomib mylan | Bortezomib pharmevid | Bortezomib Sandoz | Velcade | Zegomib</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bortero | Bortezomib Alvogen | Myborte | Tevazomib | Velcade</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bortezomib neapoli | Velcade</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Biemib | Boractib | Borcade | Velcade | Veltezo</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Velcade</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bortenat | Bortero | Bortezomib Alvogen | Bortezovista | Brecer | Namibor</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Botemib</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Botemib</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Bertred | Bortiv | Bortrac | Valoma | Valtib</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20880120">
<a name="20880120"></a>Agathocleous A, Rohatiner A, Rule S, et al. Weekly Versus Twice Weekly Bortezomib Given in Conjunction With Rituximab, in Patients With Recurrent follicular Lymphoma, Mantle Cell Lymphoma and Waldenström Macroglobulinaemia. <i>Br J Haematol</i>. 2010;151(4):346-353.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20880120/pubmed" id="20880120" target="_blank">20880120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15985470">
<a name="15985470"></a>Andre P, Cisternino S, Chiadmi F, et al. Stability of Bortezomib 1-mg/mL Solution in Plastic Syringe and Glass Vial. <i>Ann Pharmacother</i>. 2005;39(9):1462-1466.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15985470/pubmed" id="15985470" target="_blank">15985470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22689676">
<a name="22689676"></a>Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival Analysis of a Randomized, Phase 3 Study of Subcutaneous versus Intravenous Bortezomib in Patients With Relapsed Multiple Myeloma. <i>Haematologica</i>. 2012;97(12):1925-1928.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22689676/pubmed" id="22689676" target="_blank">22689676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34480762">
<a name="34480762"></a>Baradaran H, Dashti-Khavidaki S, Taher M, Talebian M, Nasiri-Toosi M, Jafarian A. Antibody-mediated rejection in adult liver transplant recipients: a case series and literature review. <i>J Clin Pharmacol</i>. 2022;62(2):254-271. doi:10.1002/jcph.1963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/34480762/pubmed" id="34480762" target="_blank">34480762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17593024">
<a name="17593024"></a>Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. <i>Br J Haematol</i>. 2007;138(2):176-185. doi:10.1111/j.1365-2141.2007.06639.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17593024/pubmed" id="17593024" target="_blank">17593024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bortezomib.1">
<a name="Bortezomib.1"></a>Bortezomib 1 or 2.5 mg injection [prescribing information]. Lake Forest, IL: Hospira Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bortezomib.2">
<a name="Bortezomib.2"></a>Bortezomib 3.5 mg injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20807892">
<a name="20807892"></a>Bringhen S, Larocca A, Rossi D, et al. Efficacy and Safety of Once-Weekly Bortezomib in Multiple Myeloma Patients. <i>Blood</i>. 2010;116(23):4745-4753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/ 20807892/pubmed" id=" 20807892" target="_blank"> 20807892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33091356">
<a name="33091356"></a>Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematol</i>. 2020;7(11):e827-e837. doi:10.1016/S2352-3026(20)30224-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/33091356/pubmed" id="33091356" target="_blank">33091356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22498745">
<a name="22498745"></a>Cavo M, Pantani L, Petrucci MT, et al; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Blood</i>. 2012;120(1):9-19. doi:10.1182/blood-2012-02-408898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22498745/pubmed" id="22498745" target="_blank">22498745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21146205">
<a name="21146205"></a>Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <i>Lancet</i>. 2010;376(9758):2075-2085. doi:10.1016/S0140-6736(10)61424-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21146205/pubmed" id="21146205" target="_blank">21146205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21336085">
<a name="21336085"></a>Chan KM, Lee CS, Wu TJ, Lee CF, Chen TC, Lee WC. Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. <i>Transplantation</i>. 2011;91(5):e29-e30. doi:10.1097/TP.0b013e318208138c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21336085/pubmed" id="21336085" target="_blank">21336085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138816">
<a name="17138816"></a>Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and Safety of Bortezomib in Multiple Myeloma Patients With Advanced Renal Failure: A Multicenter Retrospective Study. <i>Blood</i>. 2006;109(9):2604-2606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17138816/pubmed" id="17138816" target="_blank">17138816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18711175">
<a name="18711175"></a>Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. <i>J Clin Oncol</i>. 2008;26(29):4784-4790.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/18711175/pubmed" id="18711175" target="_blank">18711175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17353550">
<a name="17353550"></a>Chen CI, Kouroukis CT, White D, et al. Bortezomib is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. <i>J Clin Oncol</i>. 2007;25(12):1570-1575. doi:10.1200/JCO.2006.07.8659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17353550/pubmed" id="17353550" target="_blank">17353550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25838326">
<a name="25838326"></a>Colvin MM, Cook JL, Chang P, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;131(18):1608-1639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25838326/pubmed" id="25838326" target="_blank">25838326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20874823">
<a name="20874823"></a>Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. <i>Eur J Haematol</i>. 2011;86(1):23-31. doi:10.1111/j.1600-0609.2010.01533.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20874823/pubmed" id="20874823" target="_blank">20874823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24004667">
<a name="24004667"></a>Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i>. 2013;122(19):3276-3782. doi:10.1182/blood-2013-05-503862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/24004667/pubmed" id="24004667" target="_blank">24004667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19858394">
<a name="19858394"></a>Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>J Clin Oncol</i>. 2009;27(36):6086-6093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19858394/pubmed" id="19858394" target="_blank">19858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976420">
<a name="26976420"></a>Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016;34(13):1544-1557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/26976420/pubmed" id="26976420" target="_blank">26976420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28017406">
<a name="28017406"></a>Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2017;389(10068):519-527. doi:10.1016/S0140-6736(16)31594-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/28017406/pubmed" id="28017406" target="_blank">28017406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32393732">
<a name="32393732"></a>Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). <i>Blood Cancer J</i>. 2020;10(5):53. doi:10.1038/s41408-020-0311-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/32393732/pubmed" id="32393732" target="_blank">32393732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24708575">
<a name="24708575"></a>Eskandary F, Bond G, Schwaiger E, et al. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. <i>Trials</i>. 2014;15:107. doi:10.1186/1745-6215-15-107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/24708575/pubmed" id="24708575" target="_blank">24708575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29242250">
<a name="29242250"></a>Eskandary F, Regele H, Baumann L, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. <i>J Am Soc Nephrol</i>. 2018;29(2):591-605. doi:10.1681/ASN.2017070818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/29242250/pubmed" id="29242250" target="_blank">29242250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17001068">
<a name="17001068"></a>Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>J Clin Oncol</i>. 2006;24(30):4867-4874.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17001068/pubmed" id="17001068" target="_blank">17001068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21042239">
<a name="21042239"></a>Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. <i>Transplantation</i>. 2010;90(12):1486-1492. doi:10.1097/TP.0b013e3181fdd9b0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21042239/pubmed" id="21042239" target="_blank">21042239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21810687">
<a name="21810687"></a>Fowler N, Kahl BS, Lee P, et al. Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study. <i>J Clin Oncol</i>. 2011;29(25):3389-3395.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21810687/pubmed" id="21810687" target="_blank">21810687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26469392">
<a name="26469392"></a>Fraunfelder FW, Yang HK. Association Between Bortezomib Therapy and Eyelid Chalazia. <i>JAMA Ophthalmol</i>. 2016;134(1):88-90. doi:10.1001/jamaophthalmol.2015.3963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/26469392/pubmed" id="26469392" target="_blank">26469392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21239695">
<a name="21239695"></a>Friedberg JW, Vose JM, Kelly JL, et al. The Combination of Bendamustine, Bortezomib, and Rituximab for Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma. <i>Blood</i>. 2011;117(10):2807-2812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21239695/pubmed" id="21239695" target="_blank">21239695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20142586">
<a name="20142586"></a>Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. <i>J Clin Oncol</i>. 2010;28(8):1422-1428. doi:10.1200/JCO.2009.25.3237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20142586/pubmed" id="20142586" target="_blank">20142586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851559">
<a name="22851559"></a>Gilbar PJ, Seger AC. Fatalities Resulting From Accidental Intrathecal Administration of Bortezomib: Strategies for Prevention. <i>J Clin Oncol</i>. 2012;30(27):3427-3428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22851559/pubmed" id="22851559" target="_blank">22851559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19190249">
<a name="19190249"></a>Golden EB, Lam PY, Kardosh A, et al. Green Tea Polyphenols Block the Anticancer Effects of Bortezomib and Other Boronic Acid-Based Proteasome Inhibitors. <i>Blood</i>. 2009;113(23):5927-5937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19190249/pubmed" id="19190249" target="_blank">19190249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19074748">
<a name="19074748"></a>Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. <i>Ann Oncol</i>. 2009;20(3):520-525. doi:10.1093/annonc/mdn656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19074748/pubmed" id="19074748" target="_blank">19074748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33189178">
<a name="33189178"></a>Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2020;396(10262):1563-1573. doi:10.1016/S0140-6736(20)32292-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/33189178/pubmed" id="33189178" target="_blank">33189178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20823406">
<a name="20823406"></a>Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib Plus Dexamethasone is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone as Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. <i>J Clin Oncol</i>. 2010;28(30):4621-4629.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20823406/pubmed" id="20823406" target="_blank">20823406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20575631">
<a name="20575631"></a>Iwamoto T, Ishibashi M, Fujieda A, et al. Drug Interaction Between Itraconazole and Bortezomib: Exacerbation of Peripheral Neuropathy and Thrombocytopenia Induced by Bortezomib. <i>Pharmacotherapy</i>. 2010;30(7):661-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20575631/pubmed" id="20575631" target="_blank">20575631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19786650">
<a name="19786650"></a>Jacobson JO, Polovich M, McNiff KK, et al. American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards. <i>J Clin Oncol</i>. 2009;27(32):5469-5475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19786650/pubmed" id="19786650" target="_blank">19786650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15690325">
<a name="15690325"></a>Jagannath S, Barlogie B, Berenson JR, et al .Bortezomib in Recurrent and/or Refractory Multiple Myeloma; Initial Clinical Experience in Patients With Impaired Renal Function. <i>Cancer</i>. 2005;103(6):1195-1200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15690325/pubmed" id="15690325" target="_blank">15690325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26844479">
<a name="26844479"></a>Jeong JC, Jambaldorj E, Kwon HY, et al. Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation. <i>Medicine (Baltimore)</i>. 2016;95(5):e2635. doi:10.1097/MD.0000000000002635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/26844479/pubmed" id="26844479" target="_blank">26844479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32730181">
<a name="32730181"></a>Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. <i>J Clin Oncol</i>. 2020;38(28):3252-3260. doi:10.1200/JCO.20.01285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/32730181/pubmed" id="32730181" target="_blank">32730181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34192431">
<a name="34192431"></a>Kastritis E, Palladini G, Minnema MC, et al; ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. <i>N Engl J Med</i>. 2021;385(1):46-58. doi:10.1056/NEJMoa2028631<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/34192431/pubmed" id="34192431" target="_blank">34192431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20085941">
<a name="20085941"></a>Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. <i>J Clin Oncol</i>. 2010;28(6):1031-1037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20085941/pubmed" id="20085941" target="_blank">20085941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22107129">
<a name="22107129"></a>Khan ML, Reeder CB, Kumar SK, et al. A Comparison of Lenalidomide/Dexamethasone versus Cyclophosphamide/Lenalidomide/Dexamethasone versus Cyclophosphamide/Bortezomib/Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Br J Haematol</i>. 2012;156(3):326-333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22107129/pubmed" id="22107129" target="_blank">22107129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31818254">
<a name="31818254"></a>Kim DG, Lee J, Park Y, et al. Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study. <i>BMC Nephrol</i>. 2019;20(1):456. doi:10.1186/s12882-019-1625-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/31818254/pubmed" id="31818254" target="_blank">31818254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32075220">
<a name="32075220"></a>Kolonko A, Słabiak-Błaż N, Karkoszka H, Więcek A, Piecha G. The preliminary results of bortezomib used as a primary treatment for an early acute antibody-mediated rejection after kidney transplantation-a single-center case series. <i>J Clin Med</i>. 2020;9(2):529. doi:10.3390/jcm9020529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/32075220/pubmed" id="32075220" target="_blank">32075220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35174191">
<a name="35174191"></a>Koslik MA, Friebus-Kardash J, Heinemann FM, Kribben A, Bräsen JH, Eisenberger U. Differential treatment effects for renal transplant recipients with DSA-positive or DSA-negative antibody-mediated rejection. <i>Front Med (Lausanne)</i>. 2022;9:816555. doi:10.3389/fmed.2022.816555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/35174191/pubmed" id="35174191" target="_blank">35174191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17614819">
<a name="17614819"></a>Kropff M, Bisping G, Schuck E, et al; Deutsche Studiengruppe Multiples Myelom. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. <i>Br J Haematol.</i> 2007;138(3):330-337. doi:10.1111/j.1365-2141.2007.06656.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17614819/pubmed" id="17614819" target="_blank">17614819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22422823">
<a name="22422823"></a>Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood.</i> 2012;119(19):4375-4382. doi:10.1182/blood-2011-11-395749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22422823/pubmed" id="22422823" target="_blank">22422823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20821326">
<a name="20821326"></a>Lamm W, Willenbacher W, Lang A, et al. Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. <i>Ann Hematol</i>. 2011;90(2):201-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20821326/pubmed" id="20821326" target="_blank">20821326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21479634">
<a name="21479634"></a>Leal TB, Remick SC, Takimoto CH, et al. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. <i>Cancer Chemother Pharmacol</i>. 2011;68(6):1439-1447.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21479634/pubmed" id="21479634" target="_blank">21479634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22394984">
<a name="22394984"></a>LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and Safety of Bortezomib in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432. <i>Clin Cancer Res</i>. 2012;18(10):2954-2963. doi:10.1158/1078-0432.CCR-11-2873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22394984/pubmed" id="22394984" target="_blank">22394984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24227817">
<a name="24227817"></a>Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. <i>Blood</i>. 2014;123(7):985-991. doi:10.1182/blood-2013-08-521468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/24227817/pubmed" id="24227817" target="_blank">24227817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29231133">
<a name="29231133"></a>Mateos MV, Dimopoulos MA, Cavo M, et al; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. <i>N Engl J Med</i>. 2018;378(6):518-528. doi:10.1056/NEJMoa1714678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/29231133/pubmed" id="29231133" target="_blank">29231133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20368561">
<a name="20368561"></a>Mateos MV, Richardson PG, Schlag R, et al. Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>J Clin Oncol</i>. 2010;28(13):2259-2266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20368561/pubmed" id="20368561" target="_blank">20368561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30932732">
<a name="30932732"></a>Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. <i>J Clin Oncol.</i> 2019;37(14):1228-1263. doi:10.1200/JCO.18.02096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/30932732/pubmed" id="30932732" target="_blank">30932732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19036114">
<a name="19036114"></a>Mikhael JR, Belch AR, Prince HM, et al. High Response Rate to Bortezomib With or Without Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Results of a Global Phase 3b Expanded Access Program. <i>Br J Haematol</i>. 2009;144(2):169-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19036114/pubmed" id="19036114" target="_blank">19036114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22331188">
<a name="22331188"></a>Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. <i>Blood</i>. 2012;119(19):4391-4394. doi:10.1182/blood-2011-11-390930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22331188/pubmed" id="22331188" target="_blank">22331188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31171419">
<a name="31171419"></a>Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study [published correction appears in <i>Lancet</i>. <i>Lancet</i>. 2019;394(10192):29-38. doi:10.1016/S0140-6736(19)31240-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/31171419/pubmed" id="31171419" target="_blank">31171419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18768528">
<a name="18768528"></a>Moreau P, Coiteux V, Hulin C, et al. Prospective Comparison of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma. <i>Haematologica</i>. 2008;93(12):1908-1911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/18768528/pubmed" id="18768528" target="_blank">18768528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27002117">
<a name="27002117"></a>Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. <i>Blood</i>. 2016;127(21):2569-2574. doi:10.1182/blood-2016-01-693580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/27002117/pubmed" id="27002117" target="_blank">27002117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23018466">
<a name="23018466"></a>Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. <i>Clin Pharmacokinet</i>. 2012;51(12):823-829. doi:10.1007/s40262-012-0010-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/23018466/pubmed" id="23018466" target="_blank">23018466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21507715">
<a name="21507715"></a>Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Relapsed Multiple Myeloma: A Randomised, Phase 3, Non-Inferiority Study. <i>Lancet Oncol</i>. 2011;12(5):431-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21507715/pubmed" id="21507715" target="_blank">21507715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33899550">
<a name="33899550"></a>Neuhaus K, Hohlfelder B, Bollinger J, Haug M 3rd, Torbic H. Antibody-mediated rejection management following lung transplantation. <i>Ann Pharmacother</i>. 2022;56(1):60-64. doi:10.1177/10600280211012410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/33899550/pubmed" id="33899550" target="_blank">33899550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20061929">
<a name="20061929"></a>Neumann J, Tarrasconi H, Bortolotto A, et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. <i>Transplantation</i>. 2010;89(1):125-126. doi:10.1097/TP.0b013e3181c280f9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20061929/pubmed" id="20061929" target="_blank">20061929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15613699">
<a name="15613699"></a>O'Connor OA, Wright J, Moskowitz C, et al. Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. <i>J Clin Oncol</i>. 2005;23(4):676-684.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15613699/pubmed" id="15613699" target="_blank">15613699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29740809">
<a name="29740809"></a>O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>Br J Haematol</i>. 2018;182(2):222-230. doi:10.1111/bjh.15261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/29740809/pubmed" id="29740809" target="_blank">29740809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17679727">
<a name="17679727"></a>Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. <i>J Clin Oncol</i>. 2007;25(25):3892-3901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17679727/pubmed" id="17679727" target="_blank">17679727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20940200">
<a name="20940200"></a>Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. <i>J Clin Oncol</i>. 2010;28(34):5101-5109. doi:10.1200/JCO.2010.29.8216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20940200/pubmed" id="20940200" target="_blank">20940200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27557302">
<a name="27557302"></a>Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016;375(8):754-766. doi:10.1056/NEJMoa160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/27557302/pubmed" id="27557302" target="_blank">27557302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22681986">
<a name="22681986"></a>Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. <i>Am J Transplant</i>. 2012;12(9):2526-2531. doi:10.1111/j.1600-6143.2012.04126.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22681986/pubmed" id="22681986" target="_blank">22681986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15764713">
<a name="15764713"></a>Pekol T, Daniels JS, Labutti J, et al. Human Metabolism of the Proteasome Inhibitor Bortezomib: Identification of Circulating Metabolites. <i>Drug Metab Dispos</i>. 2005;33(6):771-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15764713/pubmed" id="15764713" target="_blank">15764713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19369963">
<a name="19369963"></a>Perrone G, Hideshima T, Ikeda H, et al. Ascorbic Acid Inhibits Activity of Bortezomib <i>in vivo</i>. <i>Leukemia</i>. 2009;23(9):1679-1686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19369963/pubmed" id="19369963" target="_blank">19369963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24798311">
<a name="24798311"></a>Philogene MC, Sikorski P, Montgomery RA, Leffell MS, Zachary AA. Differential effect of bortezomib on HLA class I and class II antibody. <i>Transplantation</i>. 2014;98(6):660-665. doi:10.1097/TP.0000000000000132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/24798311/pubmed" id="24798311" target="_blank">24798311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21778706">
<a name="21778706"></a>Piro E, Molica S. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?. <i>Acta Haematol</i>. 2011;126(3):163-168. doi:10.1159/000328417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21778706/pubmed" id="21778706" target="_blank">21778706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35020191">
<a name="35020191"></a>Pratt G, El-Sharkawi D, Kothari J, et al; Diagnosis and management of Waldenström macroglobulinaemia- a British Society for Haematology guideline. <i>Br J Haematol</i>. 2022;197(2):171-187. doi:10.1111/bjh.18036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/35020191/pubmed" id="35020191" target="_blank">35020191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21562045">
<a name="21562045"></a>Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and Safety of Once-Weekly and Twice-Weekly Bortezomib in Patients With Relapsed Systemic AL Amyloidosis: Results of a Phase 1/2 Study. <i>Blood</i>. 2011;118(4):865-873. doi:10.1182/blood-2011-02-334227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21562045/pubmed" id="21562045" target="_blank">21562045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25202139">
<a name="25202139"></a>Reece DE, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. <i>Blood</i>. 2014;124(16):2498-2506. doi:10.1182/blood-2014-04-568329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25202139/pubmed" id="25202139" target="_blank">25202139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19225538">
<a name="19225538"></a>Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. <i>Leukemia</i>. 2009;23(7):1337-1341. doi:10.1038/leu.2009.26<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19225538/pubmed" id="19225538" target="_blank">19225538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20413666">
<a name="20413666"></a>Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. <i>Blood</i>. 2010;115(16):3416-3417. doi:10.1182/blood-2010-02-271676<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20413666/pubmed" id="20413666" target="_blank">20413666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31097405">
<a name="31097405"></a>Richardson PG, Oriol A, Beksac M, et al; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2019;20(6):781-794. doi:10.1016/S1470-2045(19)30152-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/31097405/pubmed" id="31097405" target="_blank">31097405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17690257">
<a name="17690257"></a>Richardson PG, Sonneveld P, Schuster M, et al. Extended Follow-up of a Phase 3 Trial in Relapsed Multiple Myeloma: Final Time-to-Event Results of the APEX Trial. <i>Blood</i>. 2007;110(10):3557-3560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17690257/pubmed" id="17690257" target="_blank">17690257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19170677">
<a name="19170677"></a>Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of Symptomatic Peripheral Neuropathy With Bortezomib in the Phase III APEX Trial in Relapsed Multiple Myeloma: Impact of a Dose-Modification Guideline. <i>Br J Haematol</i>. 2009;144(6):895-903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19170677/pubmed" id="19170677" target="_blank">19170677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15958804">
<a name="15958804"></a>Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. <i>N Engl J Med</i>. 2005;352(24):2487-249824429336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15958804/pubmed" id="15958804" target="_blank">15958804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20385792">
<a name="20385792"></a>Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i>. 2010;116(5):679-686. doi:10.1182/blood-2010-02-268862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20385792/pubmed" id="20385792" target="_blank">20385792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429336">
<a name="24429336"></a>Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i>. 2014;123(10):1461-1469. doi:10.1182/blood-2013-07-517276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/24429336/pubmed" id="24429336" target="_blank">24429336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25738670">
<a name="25738670"></a>Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. <i>N Engl J Med</i>. 2015;372(10):944-953. doi:10.1056/NEJMoa1412096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25738670/pubmed" id="25738670" target="_blank">25738670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30348538">
<a name="30348538"></a>Robak T, Jin J, Pylypenko H, et al; LYM-3002 investigators. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncol</i>. 2018;19(11):1449-1458. doi:10.1016/S1470-2045(18)30685-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/30348538/pubmed" id="30348538" target="_blank">30348538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi:10.1093/annonc/mdw270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31484647">
<a name="31484647"></a>Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i>. 2019;134(16):1337-1345. doi:10.1182/blood.2019000241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/31484647/pubmed" id="31484647" target="_blank">31484647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22791289">
<a name="22791289"></a>Rosiñol L, Oriol A, Teruel AI, et al; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i>. 2012;120(8):1589-1596. doi:10.1182/blood-2012-02-408922<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22791289/pubmed" id="22791289" target="_blank">22791289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25024076">
<a name="25024076"></a>Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. <i>J Clin Oncol</i>. 2014;32(25):2712-2717. doi:10.1200/JCO.2013.54.8164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25024076/pubmed" id="25024076" target="_blank">25024076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25803498">
<a name="25803498"></a>Sadaka B, Ejaz NS, Shields AR, et al. A Banff Component Scoring-based histologic assessment of bortezomib-based antibody-mediated rejection therapy. <i>Transplantation</i>. 2015;99(8):1691-1699. doi:10.1097/TP.0000000000000694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25803498/pubmed" id="25803498" target="_blank">25803498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23233713">
<a name="23233713"></a>San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. <i>J Clin Oncol</i>. 2013;31(4):448-455. doi:10.1200/JCO.2012.41.6180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/23233713/pubmed" id="23233713" target="_blank">23233713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25803498">
<a name="25803498"></a>Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N; ADDIKD Guideline Working Group. International consensus guideline for anticancer drug dosing in kidney dysfunction 2022. https://www.eviq.org.au/clinical-resources/addikd-guideline/4174-anticancer-drug-dosing-in-kidney-dysfunction. Published 2022. Accessed October 23, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25803498/pubmed" id="25803498" target="_blank">25803498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36413710">
<a name="36413710"></a>Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. <i>J Clin Oncol</i>. 2023;41(8):1600-1609. doi:10.1200/JCO.21.02734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/36413710/pubmed" id="36413710" target="_blank">36413710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22802322">
<a name="22802322"></a>Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. <i>J Clin Oncol</i>. 2012;30(24):2946-2955. doi:10.1200/JCO.2011.39.6820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22802322/pubmed" id="22802322" target="_blank">22802322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22202499">
<a name="22202499"></a>Stuckey LJ, Kamoun M, Chan KM. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. <i>Ann Pharmacother</i>. 2012;46(1):e2. doi:10.1345/aph.1Q509<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22202499/pubmed" id="22202499" target="_blank">22202499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taro.1">
<a name="Taro.1"></a>Taro-Bortezomib (bortezomib for injection) [product monograph]. Brampton, Ontario, Canada: Taro Pharmaceuticals Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33469943">
<a name="33469943"></a>Timofeeva OA, Choe J, Alsammak M, et al. Guiding therapeutic plasma exchange for antibody-mediated rejection treatment in lung transplant recipients - a retrospective study. <i>Transpl Int</i>. 2021;34(4):700-708. doi:10.1111/tri.13825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/33469943/pubmed" id="33469943" target="_blank">33469943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19506160">
<a name="19506160"></a>Treon SP, Ioakimidis L, Soumerai JD, et al. Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. <i>J Clin Oncol</i>. 2009;27(23):3830-3835. doi:10.1200/JCO.2008.20.4677<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19506160/pubmed" id="19506160" target="_blank">19506160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16103134">
<a name="16103134"></a>Uttamsingh V, Lu C, Miwa G, et al. Relative Contributions of the Five Major Hyman Cytochromes P450, 1A2, 2C9, 2C19, and 3A4, to the Hepatic Metabolism of the Proteosome Inhibitor Bortezomib. <i>Drug Metab Dispos</i>. 2005;33(11):1723-1728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/16103134/pubmed" id="16103134" target="_blank">16103134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27988971">
<a name="27988971"></a>Vacha M, Chery G, Hulbert A, et al. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: does it work? <i>Clin Transplant</i>. 2017;31(3). doi:10.1111/ctr.12886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/27988971/pubmed" id="27988971" target="_blank">27988971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20926455">
<a name="20926455"></a>Vanderloo JP, Pomplun ML, Vermeulen LC, et al. Stability of Unused Reconstituted Bortezomib in Original Manufacturer Vials. <i>J Oncol Pharm Pract</i>. 2011;17(4):400-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20926455/pubmed" id="20926455" target="_blank">20926455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Velcade.1">
<a name="Velcade.1"></a>Velcade (bortezomib) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Velcade.2">
<a name="Velcade.2"></a>Velcade (bortezomib) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22331187">
<a name="22331187"></a>Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. <i>Blood</i>. 2012;119(19):4387-4390. doi:10.1182/blood-2011-10-388462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22331187/pubmed" id="22331187" target="_blank">22331187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32325490">
<a name="32325490"></a>Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i>. 2020;136(8):936-945. doi:10.1182/blood.2020005288<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/32325490/pubmed" id="32325490" target="_blank">32325490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21852274">
<a name="21852274"></a>Waiser J, Budde K, Schütz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. <i>Nephrol Dial Transplant</i>. 2012;27(3):1246-1251. doi:10.1093/ndt/gfr465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21852274/pubmed" id="21852274" target="_blank">21852274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20145517">
<a name="20145517"></a>Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. <i>Transplantation</i>. 2010;89(3):277-284. doi:10.1097/TP.0b013e3181c6ff8d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20145517/pubmed" id="20145517" target="_blank">20145517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25534446">
<a name="25534446"></a>Woodle ES, Shields AR, Ejaz NS, et al. Prospective iterative trial of proteasome inhibitor-based desensitization. <i>Am J Transplant</i>. 2015;15(1):101-118. doi:10.1111/ajt.13050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25534446/pubmed" id="25534446" target="_blank">25534446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17709797">
<a name="17709797"></a>Zinzani PL, Musuraca G, Tani M, et al. Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma. <i>J Clin Oncol</i>. 2007;25(27):4293-4297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17709797/pubmed" id="17709797" target="_blank">17709797</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8509 Version 411.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
